Rivaroxaban and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is reported as a side effect among people who take Rivaroxaban (rivaroxaban), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Amlodipine, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Agranulocytosis when taking Rivaroxaban. It is created by eHealthMe based on reports of 26,430 people who have side effects when taking Rivaroxaban from the FDA, and is updated regularly.

What is Rivaroxaban?

Rivaroxaban has active ingredients of rivaroxaban. It is often used in blood clots. eHealthMe is studying from 26,544 Rivaroxaban users. Check the latest studies of Rivaroxaban.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 2,321 drugs and 3,597 conditions by eHealthMe. Check the latest studies of Agranulocytosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

26,430 people reported to have side effects when taking Rivaroxaban.
Among them, 219 people (0.83%) have Agranulocytosis.

Could Rivaroxaban cause Agranulocytosis?

Among these 219 people:

How long have people been on Rivaroxaban when they have Agranulocytosis? *

Click here to view more results

What is the gender of people who have Agranulocytosis when taking Rivaroxaban? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Rivaroxaban and have Agranulocytosis?

- Check whether Agranulocytosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rivaroxaban:

Rivaroxaban (26,544 reports)

Agranulocytosis treatments and more:

Agranulocytosis (213,267 reports)

How severe was Agranulocytosis and when was it recovered:

Agranulocytosis in Rivaroxaban

Expand to all the drugs that have ingredients of rivaroxaban:

Agranulocytosis and drugs with ingredients of rivaroxaban (959 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rivaroxaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Agranulocytosis:

Agranulocytosis (2,321 drugs)

Browse all the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,597 conditions)

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on rivaroxaban (the active ingredients of Rivaroxaban) and Rivaroxaban (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.